Abstract
Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120). Plateletpheresis was not done. Hematologic complete response (platelet count <450 x 109/L for 3 consecutive months) was achieved in 92% of the cases, in a median time of 12 weeks (range, 2-22). However, continuous low-dose maintenance therapy with PB was necessary to avoid recurrences of the disease. Major thrombocythemia-related complications were observed in 20% of the cases; the 5-year overall and complication-free survival rates were 92% and 75%, respectively. No acute or chronic toxicity was observed; no drug-induced amenorrhea and subsequent acute leukemia occurred. PB does appear to be efficacious in essential thrombocythemia; however, the evaluation of its leukemogenic risk will await further experience.
| Original language | English |
|---|---|
| Pages (from-to) | 1339-1342 |
| Number of pages | 4 |
| Journal | Cancer Treatment Reports |
| Volume | 68 |
| Issue number | 11 |
| Publication status | Published - 1984 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Efficacy trial of pipobroman in essential thrombocythemia : A study of 24 patients. / Brusamolino, E.; Canevari, A.; Salvaneschi, L.; Merante, S.; Bernasconi, C.
In: Cancer Treatment Reports, Vol. 68, No. 11, 1984, p. 1339-1342.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy trial of pipobroman in essential thrombocythemia
T2 - A study of 24 patients
AU - Brusamolino, E.
AU - Canevari, A.
AU - Salvaneschi, L.
AU - Merante, S.
AU - Bernasconi, C.
PY - 1984
Y1 - 1984
N2 - Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120). Plateletpheresis was not done. Hematologic complete response (platelet count <450 x 109/L for 3 consecutive months) was achieved in 92% of the cases, in a median time of 12 weeks (range, 2-22). However, continuous low-dose maintenance therapy with PB was necessary to avoid recurrences of the disease. Major thrombocythemia-related complications were observed in 20% of the cases; the 5-year overall and complication-free survival rates were 92% and 75%, respectively. No acute or chronic toxicity was observed; no drug-induced amenorrhea and subsequent acute leukemia occurred. PB does appear to be efficacious in essential thrombocythemia; however, the evaluation of its leukemogenic risk will await further experience.
AB - Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120). Plateletpheresis was not done. Hematologic complete response (platelet count <450 x 109/L for 3 consecutive months) was achieved in 92% of the cases, in a median time of 12 weeks (range, 2-22). However, continuous low-dose maintenance therapy with PB was necessary to avoid recurrences of the disease. Major thrombocythemia-related complications were observed in 20% of the cases; the 5-year overall and complication-free survival rates were 92% and 75%, respectively. No acute or chronic toxicity was observed; no drug-induced amenorrhea and subsequent acute leukemia occurred. PB does appear to be efficacious in essential thrombocythemia; however, the evaluation of its leukemogenic risk will await further experience.
UR - http://www.scopus.com/inward/record.url?scp=0021739763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021739763&partnerID=8YFLogxK
M3 - Article
VL - 68
SP - 1339
EP - 1342
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
SN - 0361-5960
IS - 11
ER -